| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Clinical application of iPS-derived cardiomyocytes (iPS-CMs) is considered to be one of the most promising approach to regenerative treatment for severe heart failure. However, its success would largely depend on safety, including prevention of tumor formation (Masuda S, et al. Nature Rev Cardiol. 2014;11:553-4). Here, we demonstrate that BET protein bromodomain antagonist is efficacious in removing residual undifferentiated cells in vitro. In this context, it was revealed that BET protein antagonist functions as a Nanog inhibitor within human iPS cells. Furthermore, co-treatment with BET protein antagonist and CDK inhibitors (CDK9 or CDK1 inhibitor) synergistically eliminated residual undifferentiated cells among human iPS-CMs. These findings imply that combination treatment in vitro with these drugs contributes to molecular-targeted treatment on “human iPS cells”.
|
